EirGen Pharma breast cancer product Eir-049 passes Fed and Fasted clinical trial for US

EirGen Pharma are pleased to announce that their oncology molecule "Eir-049" has successfully completed fed and fasted clinical studies in November 2008 to support licensing in the US market. This product was successful developed as a treatment for advanced breast cancer and adds to the portfolio of successful clinical trial oncology products.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.